LUSTIG MARC enters BRIACELL THERAPEUTICS CORP. with 1.64M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Indirect Derivatives
Filed: 8/2/2022ACC: 0001493152-22-021000
1.64M
Baseline shares
0.00
Direct ownership
0 positions
20K
Derivative underlying
1 instrument
1
Security positions
1.64M indirect
Non-Derivative Holdings1
Common Shares
IndirectShares owned1.64M
Total
1.64M indirect1.64M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Shares | 1.64M | Indirect |
| Total | 1.64M | 1.64M indirect |
Derivative Holdings1
Warrant
IndirectUnderlying security
Common Shares
Underlying shares
20K
Shares owned
N/A
Exercise price
5.31
Expiration
—
Exercise window
—
Total
Underlying
20K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Warrant Indirect | Common Shares | 5.31 | — | — | 20K | N/A |
| Total | 20K | 0.00 | ||||